Jul
11
2019
On demand

Closing the production gap in gene therapy – A scalable helper virus-free AAV production platform

Sponsor
Closing the production gap in gene therapy – A scalable helper virus-free AAV production platform

With gene therapy projects moving towards more common diseases, such as Rheumatoid Arthritis, Parkinson´s disease or Alzheimer´s disease, there is a growing need for large-scale viral vector production, in particular for adeno-associated viral (AAV) vectors. However, current production systems rely on transient plasmid transfection or helper viruses and are thus hardly scalable. The webinar will address solutions to overcome this production gap in gene therapy.

Watch this On Demand Webinar with Dr Nicole Faust, CEO & CSO at CEVEC, Dr Clive Glover, Director of Strategy at Pall, Dr Andy Topping, Chief Scientific Officer at FUJIFILM Diosynth Biotechnologies and Dr Philip Wills, Chief Commercial Officer at Paragon Bioservices as you learn how CEVEC´s stable, helper virus-free AAV platform overcomes scalability issues by moving AAV production to stable producer cells.


Nicole Faust
Nicole Faust
CEO at CEVEC Pharmaceuticals GmbH
Clive Glover
Clive Glover
Director, Strategy at Pall Biotech
Andy Topping
Andy Topping
CSO at Fujifilm Diosynth Biotechnologies
Philip Wills
Philip Wills
Chief Commercial Officer at Catalent Pharma Paragon Bioservices

SPEAKERS

Nicole Faust
Nicole Faust
CEO at CEVEC Pharmaceuticals GmbH
Clive Glover
Clive Glover
Director, Strategy at Pall Biotech
Andy Topping
Andy Topping
CSO at Fujifilm Diosynth Biotechnologies
Philip Wills
Philip Wills
Chief Commercial Officer at Catalent Pharma Paragon Bioservices

You might also like